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Merkel cell polyomavirus (MCPyV) DNA was detected 
in 7 (1.3%) of 526 respiratory tract samples from patients 
in Australia with upper or lower respiratory tract symptoms. 
Partial T antigen and major capsid protein sequences of 
MCPyV identiﬁ   ed in respiratory secretions showed high 
homology (99%–100%) to those found in Merkel cell car-
cinoma.
I
n the past 2 years, several previously unknown human 
polyomaviruses (PyVs) have been identiﬁ  ed: KI virus 
(KIPyV) (1) and WU virus (WUPyV) (2) from respira-
tory samples, and more recently, Merkel cell polyomavirus 
(MCPyV), most commonly from Merkel cell carcinoma tis-
sue (3). MCPyV has been found in integrated and episomal 
states (3); however, a mode of transmission for MCPyV has 
not yet been proposed. In this study, we sought to identify 
MCPyV in respiratory specimens by using real-time PCR.
The Study
This study was conducted exclusively at the Sir Albert 
Sakzewski Virus Research Centre, Royal Children’s Hos-
pital and Health Service, Brisbane, Queensland, Australia. 
The necessary ethical approval for this study was obtained 
from the Ethics Committee of the Royal Children’s Hos-
pital.
Specimens tested in this study (n = 526) were collected 
from January through December 2003 from 418 pediatric 
patients (birth to 14 years of age) (n = 450; age range 3 
days–13.5 years; mean 1.7 years; median 0.8 years) and 
71 adult patients (n = 76; age range 14.3 years–80.1 years; 
mean 47.1 years; median 52.5 years) who were hospital-
ized or sought treatment at hospitals in Queensland, Aus-
tralia, for upper or lower respiratory tract symptoms. Most 
(95.6%) samples were nasopharyngeal aspirates (NPAs); 
the remainder were bronchoalveolar lavage specimens, 
bronchial washing specimens, and endotracheal aspirates. 
These samples were collected as part of a previous study 
that tested for inﬂ  uenza viruses A and B, adenoviruses, 
human metapneumovirus, respiratory syncytial virus, and 
parainﬂ  uenza viruses 1, 2, and 3, in addition to KIPyV and 
WUPyV (4).
Samples were screened by using an MCPyV real-
time PCR that was speciﬁ  c for the VP2/3 region. Brief-
ly, 10 pmol of each primer MCPyV-2.0–4367F (5′-
GGCAGCATCCCGGCTTA-3′) and MCPyV-2.0–4399R 
(5′-CCAAAAAGAAAAGCATCATCCA-3′) and 4 pmol 
of dual-labeled probe MCPyV-2.0–4371-Prb (5′-FAM-
ATACATTGCCTTTTGGGTGTTTT-BHQ1-3′) in a 25-
μL reaction using QIAGEN Quantitect Probe master mix 
(QIAGEN, Doncaster, Victoria, Australia) with 2 μL of 
template were run on a LightCycler 480 (Roche Diagnos-
tics, Castle Hill, New South Wales, Australia) under the 
following conditions: incubation at 95°C for 15 min, fol-
lowed by 45 cycles of 95°C for 15 s and 60°C for 1 min. 
Quantitative real-time PCR was not performed because 
of limited applicability due to inherent variability in re-
spiratory sample collection. The presence of MCPyV in 
samples positive by real-time PCR was then conﬁ  rmed 
by using partial large T antigen (LT3) and major capsid 
protein (VP1) conventional MCPyV detection PCR assays 
of Feng et al. (3). All PCRs were performed in a unidi-
rectional workﬂ  ow through dedicated suites for reagent 
preparation, PCR setup, and ampliﬁ   cation. Ten random 
real-time PCR–negative samples, 10 water control sam-
ples, and template-negative control samples were used to 
exclude amplicon or sample cross-contamination. A clini-
cal sample that was positive for MCPvV by all 3 assays 
and conﬁ  rmed by sequencing was used as a positive control 
for all PCRs.
Thirty-one (5.9%) samples produced positive results 
in the real-time PCR screening. Of these, 8 (1.5%) could 
be conﬁ  rmed by only 1 conventional PCR, and 7 (1.3%) 
yielded positive results in all 3 MCPyV PCRs. All positive 
detections were in NPA samples. This variation in detection 
rates could have been due to the unforeseen nonspeciﬁ  city 
of the real-time PCR, or to the inherent lower sensitivity of 
conventional PCRs, because most real-time PCR–positive 
samples produced late signals at cycle threshold values 
≈40. We chose a conservative algorithm, in which a sample 
must have been positive in all 3 assays to be considered a 
true positive. This rule may have led to an underestimation 
of MCPyV prevalence in this sample population.
All MCPyV-positive samples were collected during 
the spring and early summer months (October–December 
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2003). Five (1.1%) of these samples originated from pedi-
atric patients, which suggests early acquisition of virus. In 
fact, all 4 MCPyV-positive patients who were not immuno-
suppressed were <2 years of age (Table 1). This age range 
coincides with ages of those who experience primary infec-
tions of many other human viruses (5,6). Of the 3 immuno-
supressed MCPyV-positive patients, 2 were adults (2.6%), 
and 1 was a 6.6-year-old child. Further information on each 
MCPyV-positive patient is listed in Table 1.
We could not discern whether the higher frequency of 
detections in adults was representative of the general adult 
population or whether the detections were overrepresented 
due to a small sample size or the immune status of the adult 
cohort. The integration status of the detected MCPyV DNA 
was not able to be ascertained; however, for 1 patient for 
whom multiple samples were tested, MCPyV was neither 
detected 2 months before nor 3 months after MCPyV-B4 
was detected, which suggests that, at least in this particular 
patient, MCPyV may have had transitory presence or ac-
tivity. Multiple samples were not available for any of the 
other MCPyV-positive patients.
Three MCPyV (MCV-B1/B2/B3)–positive samples 
were further investigated through bidirectional sequenc-
ing of their LT3 (FJ009185, FJ009186, and FJ009187, re-
spectively) and VP1 (FJ009188, FJ009189, and FJ009190, 
respectively) assay ampliﬁ  cation products. The sequences 
of the 3 samples showed high homology to those of the 2 
previously described MCPyV strain sequences, MCC350 
(EU375803) and MCC339 (EU375804) (3); similarities 
in the LT3 and VP1 target regions ranged from 99.6%–
100.0% and 99.0%–99.6%, respectively (Table 2).
Clinical notes were available for 5 of the 7 MCPyV-
positive patients and indicated that these patients exhibited 
a variety of upper and lower respiratory tract symptoms. 
MCPyV was the sole viral agent detected in 6 of the 7 sam-
ples (Table 1). However, due to limited remaining volumes, 
study samples were not screened for other known respira-
tory pathogens, including coronaviruses and rhinoviruses, 
which may have led to a higher codetection rate, similar to 
that for KIPyV (1,4) and WUPyV (2,4).
Conclusions
To date, MCPyV has been most commonly studied 
and detected in the context of Merkel cell carcinoma (3,7), 
but it has also been identiﬁ  ed in Kaposi sarcoma tissue (3), 
primary squamous cell carcinoma tissue (7), keratoacan-
thoma tissue from an organ  recipient (8), in normal sun-
exposed skin (7), and in a small number of control tissues 
(normal skin, small bowel, hemorrhoids, appendix, and gall 
bladder) (3). In this study, MCPyV was detected in 1.3% of 
respiratory samples collected from symptomatic persons. 
This description of the presence of MCPyV in the respira-
tory tract raises questions about the transmission and respi-
ratory pathogenicity of this newly described PyV.
Analogous to MCPyV, both KIPyV (1,4) and WUPyV 
(2,4) have been found globally in respiratory specimens 
with a high prevalence of codetected viruses, but clear evi-
dence for a causal association with respiratory illness has 
yet to be identiﬁ  ed. These PyVs may be merely transmitted 
through the respiratory route or detected during periods of 
reactivation (9). Similarly, JC and BK PyVs are suspected 
of being transmitted by inhalation and are occasionally de-
tected in respiratory samples, yet patients generally remain 
asymptomatic or exhibit nonspeciﬁ  c upper respiratory tract 
symptoms (10,11). Like these other PyVs, MCPyV may 
potentially be transmitted through the respiratory route and 
become latent in other sites, such as epidermal tissue, by 
systemic spread, in a similar fashion to murine PyV (12). 
Clearly, further studies using larger sample populations, 
expanded respiratory pathogen detection methods, and 
control groups are needed to elucidate what role, if any, 
MCPyV plays in upper and lower respiratory tract illness.
On the basis of the ages and immune status of the 
MCPyV-positive patients, we can hypothesize that MCPyV 
may have an infectious cycle similar to that of other human 
PyVs, in which the virus is acquired early in life, under-
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Table 1. Detection of MCPyV in nasopharyngeal aspirates in persons with respiratory signs and symptoms, Queensland, Australia, 
2003*†
Patient characteristics 
Sample Ct Codetections Age Sex Immune status Clinical history  Signs and symptoms
MCV-B1 (LT3: FJ009185, 
VP1: FJ009188) 
29.0 – 52.0 y  M Suppressed Acute myeloid 
leukemia
Flu-like
MCV-B2 (LT3: FJ009186, 
VP1: FJ009189) 
33.0 – 6.6 y  F Suppressed Heart transplant, 
T-cell lymphoma 
Coryza, fever, 
sore throat, ear pain 
MCV-B3 (LT3: FJ009187, 
VP1: FJ009190) 
31.5 – 47.7 y  M Suppressed Heart transplant  –
MCV-B4 36.9 – 8 mo, 8 d  M Competent – Bronchiolitis
MCV-B5 37.5 – 1 mo, 26 d  M Competent – Rhinorrhea, cough 
MCV-B6 37.4 – 9 mo, 27 d  F Competent –
MCV-B7 38.9 Adenovirus,
WUPyV 
1.6 y  F Competent – Fever, convulsions 
*MCPyV, Merkel cell polyomavirus; Ct, cycle threshold; WUPyV, WU polyomavirus. 
†Clinical histories and symptoms were noted when available. Associated GenBank accession numbers are shown in parentheses.  goes a period of latency, and then becomes reactivated in 
the event of immunosuppression (10). Sequence data from 
positive specimens indicate that MCPyV found in respira-
tory secretions is similar to the viruses identiﬁ  ed within 
Merkel cell carcinomas. Whether and how the virus is 
translated from the respiratory tract to skin cells, if it is able 
to be transported systemically, and its role in the malignant 
transformation of Merkel cells are all questions worthy of 
further investigation.
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Table 2. Nucleotide variation in LT3 and VP1 sequences from 3 MCPyV strains detected in respiratory secretions from patients, 
Queensland, Australia, 2993*† 
Nucleotide position and change 
LT3 VP1 
Isolate name  843    3825 3875 3909 4022 
MCC350‡ (EU375803)  G   T  C  C  T 
MCC339‡ (EU375804)  C    C  G  T  A 
MCV-B1 (LT3: FJ009185, VP1: FJ009188)  C    C  –  –  – 
MCV-B2 (LT3: FJ009186, VP1: FJ009189)  C    C  G  –  A 
MCV-B3 (LT3: FJ009187, VP1: FJ009190)  C    C  –  –  – 
*LT3, partial large T antigen; VP1, major capsid protein; MCPyV, Merkel cell polyomavirus. 
†Nucleotide changes are in relation to the prototype strain (boldface). Dashes indicate homology with MCC350. Nucleotide positions are given in a 5ƍ ĺ 
3ƍ early to late orientation, respective to alignment with MCC350. GenBank accession numbers are shown in parentheses. 
‡Original MCPyV strain sequences described by Feng et al. (3). 
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